KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Assets (2016 - 2025)

Historic Current Assets for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $28.7 billion.

  • Astrazeneca's Current Assets rose 1121.31% to $28.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $28.7 billion, marking a year-over-year increase of 1121.31%. This contributed to the annual value of $28.7 billion for FY2025, which is 1121.31% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Current Assets is $28.7 billion, which was up 1121.31% from $29.9 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Current Assets peaked at $29.9 billion during Q3 2025, and registered a low of $18.7 billion during Q1 2021.
  • Its 5-year average for Current Assets is $24.6 billion, with a median of $25.2 billion in 2023.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 15329.75% in 2021, then tumbled by 2422.91% in 2022.
  • Astrazeneca's Current Assets (Quarter) stood at $26.2 billion in 2021, then fell by 13.91% to $22.6 billion in 2022, then rose by 10.89% to $25.1 billion in 2023, then grew by 3.09% to $25.8 billion in 2024, then grew by 11.21% to $28.7 billion in 2025.
  • Its Current Assets stands at $28.7 billion for Q4 2025, versus $29.9 billion for Q3 2025 and $28.9 billion for Q2 2025.